| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/0163-7258(95)02053-5 |
| P698 | PubMed publication ID | 8984506 |
| P2093 | author name string | De Luca A | |
| Coupar IM | |||
| P433 | issue | 2 | |
| P921 | main subject | opioid | Q427523 |
| P304 | page(s) | 103-115 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Pharmacology & Therapeutics | Q3378596 |
| P1476 | title | Insights into opioid action in the intestinal tract | |
| P478 | volume | 69 |
| Q36090988 | 6β-N-heterocyclic substituted naltrexamine derivative NAP as a potential lead to develop peripheral mu opioid receptor selective antagonists |
| Q41632156 | A Case of Stercoral Perforation Detected on CT Requiring Proctocolectomy in a Heroin-Dependent Patient |
| Q44339976 | A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation |
| Q98646721 | A retrospective evaluation of the effect of perianesthetic hydromorphone administration on the incidence of postanesthetic signs of colic in horses |
| Q44136578 | Active bicarbonate-dependent secretion evoked by 5-hydroxytryptamine in porcine ileal mucosa is mediated by opioid-sensitive enteric neurons |
| Q36904890 | Acute infectious pediatric gastroenteritis: beyond oral rehydration therapy |
| Q38040321 | Agents that act luminally to treat diarrhoea and constipation |
| Q36078760 | Alvimopan, a selective peripherally acting mu-opioid antagonist |
| Q57480158 | Alvimopan∗∗Alvimopan is the official USAN name adopted as of press time. (ADL 8-2698) Is a Novel Peripheral Opioid Antagonist |
| Q33649070 | Analgesic agents for the postoperative period. Nonopioids |
| Q56113559 | Analgesics and Antipyretics |
| Q35194392 | Anticipating and treating opioid-associated adverse effects |
| Q57124099 | Assessment of Gastrointestinal Motility Using Three Different Assays In Vitro |
| Q46147978 | Association of bowel rest and ketorolac analgesia with short hospital stay after laparoscopic donor nephrectomy |
| Q35048680 | Characterisation of opioid receptors involved in modulating circular and longitudinal muscle contraction in the rat ileum |
| Q38263244 | Clinical and pharmacokinetic considerations of novel formulations of fentanyl for breakthrough cancer pain |
| Q35233407 | Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone |
| Q26995944 | Clinical potential of naloxegol in the management of opioid-induced bowel dysfunction |
| Q46087616 | Complications of laparoscopic living donor nephrectomy and their management: the UCLA experience |
| Q36758292 | Constipation and palliative care - where are we now? |
| Q84478534 | Constipation in people prescribed opioids |
| Q35770714 | Constipation: opioid antagonists in people prescribed opioids |
| Q37686927 | Critical illness, gastrointestinal complications, and medication therapy during enteral feeding in critically ill adult patients |
| Q44349526 | Delta-opioid receptor mRNA expression and immunohistochemical localization in porcine ileum |
| Q36480105 | Design, synthesis, and biological evaluation of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan derivatives as peripheral selective μ opioid receptor Agents |
| Q37079261 | Development of drugs for gastrointestinal motor disorders: translating science to clinical need |
| Q38437111 | Editor's Choice-Chest pain relief in patients with acute myocardial infarction. |
| Q43591803 | Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine |
| Q79521867 | Effect of naloxone-3-glucuronide and N-methylnaloxone on the motility of the isolated rat colon after morphine |
| Q36699289 | Effect of thienorphine on intestinal transit and isolated guinea-pig ileum contraction |
| Q37601903 | Effectiveness of two opioid antagonists in treating opioid-induced constipation |
| Q36854395 | Effects of methylnaltrexone on guinea pig gastrointestinal motility |
| Q44330488 | Effects of mu-opioid receptor agonists on intestinal secretion and permeability during acute intestinal inflammation in mice |
| Q34146166 | Efficacy and safety of prucalopride in patients with chronic noncancer pain suffering from opioid-induced constipation |
| Q44582043 | Evidence for a glutamatergic modulation of the cholinergic function in the human enteric nervous system via NMDA receptors. |
| Q40836602 | Functional gut disorders: from motility to sensitivity disorders. A review of current and investigational drugs for their management |
| Q36751995 | Genetic and Non-genetic Factors Associated With Constipation in Cancer Patients Receiving Opioids |
| Q35027860 | Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration |
| Q26748904 | Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors |
| Q34186826 | In Vivo Effects of Cagaita (Eugenia dysenterica, DC.) Leaf Extracts on Diarrhea Treatment |
| Q34470202 | Incidence, prevalence, and management of opioid bowel dysfunction |
| Q38762441 | Indications for Opioid Antagonists |
| Q44330417 | Inhibition of motility in isolated horse small intestine is mediated by κ but not µ opioid receptors. |
| Q35044112 | Involvement of mu- and kappa-, but not delta-, opioid receptors in the peristaltic motor depression caused by endogenous and exogenous opioids in the guinea-pig intestine. |
| Q35738929 | Lessons from the porcine enteric nervous system |
| Q34693351 | Long-term evaluation of combined prolonged-release oxycodone and naloxone in patients with moderate-to-severe chronic pain: pooled analysis of extension phases of two Phase III trials |
| Q44337419 | Low-dose oral naloxone reverses opioid-induced constipation and analgesia |
| Q35819660 | Management of opioid-induced bowel dysfunction in cancer patients |
| Q34523889 | Management of opioid-induced gastrointestinal effects in patients receiving palliative care |
| Q44343238 | Methyl-orvinol-Dual activity opioid receptor ligand inhibits gastrointestinal transit and alleviates abdominal pain in the mouse models mimicking diarrhea-predominant irritable bowel syndrome |
| Q89993957 | Methylation Products of 6β- N-Heterocyclic Substituted Naltrexamine Derivatives as Potential Peripheral Opioid Receptor Modulators |
| Q35026245 | Methylnaltrexone in the treatment of opioid-induced constipation |
| Q79274536 | Milk Bioactive Peptides and β-Casomorphins Induce Mucus Release in Rat Jejunum |
| Q46958243 | Modulation of enteric cholinergic neurons by hetero- and autoreceptors: cooperation among inhibitory inputs |
| Q43019372 | Monoglyceride lipase deficiency causes desensitization of intestinal cannabinoid receptor type 1 and increased colonic μ-opioid receptor sensitivity |
| Q34428483 | Morphine decreases enteric neuron excitability via inhibition of sodium channels. |
| Q34730482 | Morphine dependence in single enteric neurons from the mouse colon requires deletion of β-arrestin2 |
| Q42702299 | Morphine-Induced Constipation Develops With Increased Aquaporin-3 Expression in the Colon via Increased Serotonin Secretion |
| Q39403721 | Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation |
| Q35778814 | Neurochemical features of endomorphin-2-containing neurons in the submucosal plexus of the rat colon |
| Q43335045 | New Formulation of Sustained Release Naloxone Can Reverse Opioid Induced Constipation Without Compromising the Desired Opioid Effects |
| Q37299608 | New approaches to the treatment of opioid-induced constipation. |
| Q36107418 | Opioid Analgesics and P-Glycoprotein Efflux Transporters: A Potential Systems-Level Contribution to Analgesic Tolerance |
| Q34786882 | Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation |
| Q28294194 | Opioid induced bowel disease: a twenty-first century physicians' dilemma. Considering pathophysiology and treatment strategies |
| Q35159547 | Opioid receptors and associated regulator of G protein signaling are involved in the cathartic colon of rats |
| Q35185222 | Opioid receptors in the gastrointestinal tract |
| Q90452095 | Opioid use is associated with incomplete capsule endoscopy examinations: a systematic review and meta-analysis |
| Q31942078 | Opioid, cannabinoid and vanilloid receptor localization on porcine cultured myenteric neurons |
| Q38511326 | Opioid-Induced Esophageal Dysfunction (OIED) in Patients on Chronic Opioids |
| Q38040843 | Opioid-induced bowel dysfunction: pathophysiology and management |
| Q35091914 | Opioid-induced bowel dysfunction: pathophysiology and potential new therapies |
| Q28209970 | Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden |
| Q37846099 | Opioid-induced constipation: challenges and therapeutic opportunities |
| Q38997203 | Opioids and GI Motility-Friend or Foe? |
| Q34605852 | Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine |
| Q36107411 | Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs |
| Q35860904 | Opioids and the gut: pharmacology and current clinical experience. |
| Q64101215 | Optimal treatment of opioid induced constipation in daily clinical practice - an observational study |
| Q58786001 | Oral methylnaltrexone does not negatively impact analgesia in patients with opioid-induced constipation and chronic noncancer pain |
| Q34040186 | Orphanin FQ/nociceptin: a novel neuromodulator of gastrointestinal function? |
| Q51037062 | Palliative stenting for late malignant gastric outlet obstruction. |
| Q53422317 | Peripherally Acting μ-Opioid Receptor Agonists Attenuate Ongoing Pain-associated Behavior and Spontaneous Neuronal Activity after Nerve Injury in Rats. |
| Q37317436 | Pharmacological challenges in chronic pancreatitis |
| Q35045783 | Pharmacological characterization of a 7-benzylidenenaltrexone-preferring opioid receptor in porcine ileal submucosa |
| Q37491434 | Physiology, signaling, and pharmacology of opioid receptors and their ligands in the gastrointestinal tract: current concepts and future perspectives |
| Q34208932 | Potentiating effect of morphine on oral Salmonella enterica serovar Typhimurium infection is μ-opioid receptor-dependent |
| Q44347595 | Prosecretory effect of loperamide in ileal and colonic mucosae of mice displaying high or low swim stress-induced analgesia associated with high and low endogenous opioid system activity |
| Q35087885 | Racecadotril versus loperamide: antidiarrheal research revisited |
| Q43299738 | Randomized placebo-controlled trial on local applications of opioids after hemorrhoidectomy |
| Q34418203 | Recent advances in the use of opioids for cancer pain |
| Q45141814 | Reduction of saquinavir exposure by coadministration of loperamide: a two-way pharmacokinetic interaction |
| Q37807415 | Regulation of electroneutral NaCl absorption by the small intestine |
| Q36178704 | Relative efficacy of some prokinetic drugs in morphine-induced gastrointestinal transit delay in mice |
| Q33450132 | Review article: the treatment of functional abdominal bloating and distension |
| Q34413460 | Sedative and cardiopulmonary effects of buprenorphine and xylazine in horses. |
| Q35236345 | Sensitization of enteric neurons to morphine by HIV-1 Tat protein. |
| Q39110222 | Spasmogenic Activity of the Seed of Terminalia chebula Retz in Rat Small Intestine: In Vivo and In Vitro Studies |
| Q73419036 | Studies investigating the possible involvement of adenosine in the antisecretory action of morphine |
| Q33954651 | Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions |
| Q41977439 | The Effect of DA-9701 in Opioid-induced Bowel Dysfunction of Guinea Pig. |
| Q36762661 | The Impact of Opioid Treatment on Regional Gastrointestinal Transit |
| Q64079646 | The Role of Opioids and Alcohol in the Development of Achalasia Type III and Esophagogastric Junction Outflow Obstruction |
| Q26851158 | The Useage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review |
| Q38225032 | The discovery and development of the N-substituted trans-3,4-dimethyl-4-(3'-hydroxyphenyl)piperidine class of pure opioid receptor antagonists |
| Q44333143 | The effect of opioid agonists and antagonists on gastrointestinal motility in mice selected for high and low swim stress-induced analgesia |
| Q39229690 | The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist |
| Q44334198 | The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone |
| Q44346649 | The opioid system in the gastrointestinal tract |
| Q46438870 | Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans |
| Q28284578 | Treatment of opioid-induced gut dysfunction |
| Q50048498 | Updates in palliative care - recent advancements in the pharmacological management of symptoms. |
| Q37857765 | Validated tools for evaluating opioid-induced bowel dysfunction |
| Q33296232 | Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas |
| Q33542009 | What peptides these deltorphins be. |
Search more.